Health care M&A activity in 1st-qtr 2014 softens compared with 4th-qtr 2013; report

23 April 2014

Health care merger and acquisition activity was a little soft in the first quarter of 2014. Deal volume was down 14% versus the previous quarter, with 239 deals announced.

However, the most recent quarter bested the same quarter a year ago, by nearly 13%, when only 212 deals were announced, according to The Health Care M&A Report, from Irving Levin Associates. Deal value actually improved compared with the fourth quarter of 2013. The early total for M&A activity in the first quarter is $49.6 billion, up 11% compared with fourth-quarter 2013. Compared with the first quarter of 2013, when buyers committed just $15.6 billion, deal value jumped 217%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >